Theleme Partners LLP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Theleme Partners LLP reported 8 stock positions worth $2.0 billion. Its top holding was Moderna (MRNA) at 42.7% of the portfolio, followed by Schwab (charles) (SCHW, 16.9%) and Wells Fargo (WFC, 13.7%). Compared with Q1 2024, it opened 1 new position, added to 4 and reduced 3. The biggest buy was a new position in Equifax (EFX) and the biggest sale Wells Fargo (WFC, shares −21%).
- Most Recent 13F
- Q2 2026
- Location
- London, X0
- CIK
- 0001511881
- Portfolio Value
- $2.0B (Q2 2024)
- SEC Filing
- 0000919574-24-004526 ↗ filed Aug 14, 2024
Holdings Value
Holdings 8 stocks · $2.0B
| MRNA Moderna Inc. | 42.68% | 7,226,861 | $858.2M | Reduce -1.3% |
| SCHW Schwab (charles) Corp. | 16.88% | 4,605,545 | $339.4M | Reduce -9.2% |
| WFC Wells Fargo & Co. | 13.74% | 4,651,610 | $276.3M | Reduce -21.3% |
| TRU Transunion | 8.41% | 2,281,159 | $169.2M | Add +64.7% |
| HRI Herc Holdings Inc. filed as HERC HLDGS INC | 7.26% | 1,095,474 | $146.0M | Add +32.3% |
| SKX Skechers USA Inc. Class A | 5.35% | 1,555,000 | $107.5M | Add +38.2% |
| EFX Equifax Inc. | 4.72% | 391,088 | $94.8M | New |
| HDB HDFC Bank Ltd.-ADR | 0.96% | 301,000 | $19.4M | Add +42.6% |
Options reported separately and not counted above: MRNA calls ($73.7M).
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
Options Activity Q1 2024 → Q2 2024
| MRNA Moderna Inc. | call | Reduce -99.6% | 6,204 | $73.7M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $1.7B | MRNA, META, UBER, AMZN, TRU |
| Q1 2026 | 9 | $1.5B | MRNA, META, UBER, TRU, AMZN |
| Q4 2025 | 9 | $1.5B | META, MRNA, FLUT, TRU, WFC |
| Q3 2025 | 10 | $1.6B | META, WFC, MRNA, TRU, UBER |
| Q2 2025 | 10 | $1.6B | MRNA, WFC, META, TRU, FLUT |
| Q1 2025 | 12 | $1.3B | MRNA, AMZN, WFC, TRU, EFX |
| Q4 2024 | 11 | $1.5B | MRNA, BAC, WFC, AMZN, EFX |
| Q3 2024 | 10 | $1.7B | MRNA, SCHW, TRU, EFX, HRI |
| Q2 2024 | 8 | $2.0B | MRNA, SCHW, WFC, TRU, HRI |
| Q1 2024 | 7 | $1.8B | MRNA, SCHW, WFC, HRI, TRU |